MORGAN NOBLE: Open Payments
NPI 1285244178 · MANILA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 24 payments from 12 companies in 2025. Trend: 2023 $542 · 2024 $682 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 3 | $76 |
| ABBVIE INC. | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $65 |
| Novo Nordisk Inc | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: Omnipod, CAPLYTA, Ozempic, REXULTI, Auvelity, FARXIGA, QULIPTA, GEMTESA.
Industry payments across AR — which companies pay providers there.
